NCT01894958
|
Phase II multicentre
|
NNZ-2566
|
Adolescent and adult males
|
NMDA antagonists
|
Recruiting
|
Neuren Pharmaceuticals (USA)
|
Pending
|
NCT01725152
|
Phase II single centre
|
Ganaxolone
|
Adolescents and children
|
GABA-A agonist
|
Recruiting
|
Marinus Pharmaceuticals (USA)
|
Pending
|
NCT02126995
|
Phase II single centre
|
Metadoxine (MG01CI)
|
Adults and adolescents
|
Ion pair of pyridoxine (vitamin 6)
|
Not yet recruiting
|
Alcobra Pharma (USA)
|
Pending
|
NCT01474746
|
Phase II single centre
|
Sertraline
|
Children
|
Selective serotonin reuptake inhibitors
|
Recruiting
|
University of California, Davis (USA)
|
Pending
|
NCT01911455
|
Phase II and III Multicentre
|
Acamprosate
|
Adolescents and children
|
NMDA receptor modulators
|
Recruiting
|
Children’s Hospital Medical Center (Cincinnati, OH, USA)
|
Pending
|
NCT01357239
|
Phase II multicentre
|
Mavoglurant (AFQ056)
|
Adolescents and adults
|
mGlur5 antagonist
|
Terminated
|
Novartis (Basel, Switzerland)
|
[62]
|
NCT01348087
|
NCT01013480
|
Phase II multicentre
|
Arbaclofen (STX209)
|
Adolescents and adults
|
GABA-B agonist
|
Terminated
|
Seaside Therapeutics (USA)
|
[63]
|
[64]
|
NCT01053156
|
Phase II single centre
|
Minocycline
|
Adolescents and children
|
Antibiotic
|
Completed
|
University of California, Davis (USA)
|
[65]
|
NCT01015430
|
Phase II multicentre
|
Basimglurant (RO4917523)
|
Adults
|
mGlur5 antagonist
|
Completed
|
Hoffmann-La Roche
|
Pending
|
NCT00895752
|
Phase IV single centre
|
Riluzole
|
Adults
|
Inhibitor of glutamate release
|
Completed
|
Indiana University (USA)
|
[66]
|
NCT01254045
|
Phase II single centre
|
Oxytocin
|
Adolescents and adults
|
Social brain neuropeptides
|
Completed
|
Stanford University (USA)
|
[67]
|
NCT01120626
|
Open label
|
Donepezil
|
Adolescents and children
|
Cholinergic drug
|
Completed
|
Stanford University (USA)
|
[68]
|